Physician profile
Ryan Ray Riahi
NPI 1457627374
$9,956.04
in general payments reported to CMS, 2019-2025
39 companies · $2,595 in 2025
The $2,595 reported for 2025 was more than what 82% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $977 · 2020: $64.31 · 2021: $549 · 2022: $953 · 2023: $2,089 · 2024: $2,730 · 2025: $2,595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,395 · Education: $18.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,395.13 |
| Education | $18.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,242.15 | 2019-2025 | |
| Janssen Biotech, INC. | $893.08 | 2022-2025 | Tremfya |
| Lilly USA, LLC | $771.77 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $724.08 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $672.36 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $617.34 | 2021-2025 | Dupixent, Libtayo |
| Pfizer INC. | $455.74 | 2019-2025 | |
| Galderma Laboratories, L.P. | $353.49 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| Amgen INC. | $336.30 | 2019-2025 | Otezla |
| Sun Pharmaceutical Industries INC. | $324.85 | 2021-2025 | Ilumya |
| Incyte Corporation | $291.06 | 2022-2025 | Opzelura |
| Leo Pharma INC. | $240.92 | 2022-2025 | Adbry, Anzupgo |
| Dermavant Sciences, INC. | $200.15 | 2024 | Vtama |
| Celgene Corporation | $195.59 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $193.15 | 2021-2025 | Cabtreo, Jublia, Arazlo |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Riahi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.